Related Experiment Video

Updated: Nov 24, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.4K

COVID-19 and Pulmonary Hypertension in Children: What Do We Know So Far?

Bibhuti B Das1

  • 1Department of Pediatric, Division of Pediatric Cardiology, Baylor College of Medicine, Texas Children's Hospital Austin Specialty Care, Austin, TX 78759, USA.

Medicina (Kaunas, Lithuania)
|December 23, 2020
PubMed

Insights

The link between COVID-19 and pediatric pulmonary hypertension (PH) remains unclear. While PH increases risks in adults, children with PH show few COVID-19 cases, possibly due to protective measures or treatments.

Area of Science:

  • Pediatric Pulmonology
  • Infectious Diseases
  • Cardiology

Background:

  • The impact of coronavirus disease 2019 (COVID-19) on pediatric pulmonary hypertension (PH) is not well understood.
  • Adults with PH face severe COVID-19 complications, but this risk cannot be directly applied to children.
  • Limited data exists on COVID-19 incidence in pediatric PH patients.

Purpose of the Study:

  • To review the pathophysiology of PH in the context of COVID-19.
  • To explore differences in COVID-19 outcomes between pediatric and adult PH patients.
  • To discuss management strategies for pediatric PH during the pandemic and its broader implications.

Main Methods:

  • Literature review and synthesis of existing data on COVID-19 and pediatric PH.
  • Analysis of potential factors contributing to low reported COVID-19 incidence in this population.
  • Discussion of current therapeutic approaches for PH in relation to viral infections.

Main Results:

  • A low number of COVID-19 cases have been reported in children with pre-existing PH.
  • Factors such as disease rarity, testing limitations, and adherence to public health guidelines may contribute to this low incidence.
  • PH itself does not appear protective against COVID-19, but PH medications might offer some protection.

Conclusions:

  • The relationship between COVID-19 and pediatric PH requires further investigation.
  • Management of pediatric PH during the pandemic necessitates careful consideration of potential risks and therapeutic options.
  • Understanding this interplay is crucial for advancing the field of pediatric pulmonary hypertension.

Keywords:
COVID-19SARS-CoV-2pediatric pulmonary hypertension

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.5K
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.7K

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
427
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
319
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.6K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
436
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.2K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.2K